Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses

Lars E. Clark, Selma Mahmutovic, Donald D. Raymond, Taleen Dilanyan, Takaaki Koma, John Manning, Sundaresh Shankar, Silvana C. Levis, Ana M. Briggiler, Delia A. Enria, Kai W. Wucherpfennig, Slobodan Paessler, Jonathan Abraham

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern.

Original languageEnglish (US)
Article number1884
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Arenavirus
fever
Antibody Binding Sites
vaccines
New World Arenaviruses
Junin virus
antibodies
Viruses
viruses
Fever
Vaccines
Antibodies
Binding Sites
Transferrin Receptors
Western hemisphere
Epitopes
Glycoproteins
Public health
public health
Public Health

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. / Clark, Lars E.; Mahmutovic, Selma; Raymond, Donald D.; Dilanyan, Taleen; Koma, Takaaki; Manning, John; Shankar, Sundaresh; Levis, Silvana C.; Briggiler, Ana M.; Enria, Delia A.; Wucherpfennig, Kai W.; Paessler, Slobodan; Abraham, Jonathan.

In: Nature Communications, Vol. 9, No. 1, 1884, 01.12.2018.

Research output: Contribution to journalArticle

Clark, LE, Mahmutovic, S, Raymond, DD, Dilanyan, T, Koma, T, Manning, J, Shankar, S, Levis, SC, Briggiler, AM, Enria, DA, Wucherpfennig, KW, Paessler, S & Abraham, J 2018, 'Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses', Nature Communications, vol. 9, no. 1, 1884. https://doi.org/10.1038/s41467-018-04271-z
Clark, Lars E. ; Mahmutovic, Selma ; Raymond, Donald D. ; Dilanyan, Taleen ; Koma, Takaaki ; Manning, John ; Shankar, Sundaresh ; Levis, Silvana C. ; Briggiler, Ana M. ; Enria, Delia A. ; Wucherpfennig, Kai W. ; Paessler, Slobodan ; Abraham, Jonathan. / Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{a382ba82c2864a7089b62d21b4209b29,
title = "Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses",
abstract = "While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern.",
author = "Clark, {Lars E.} and Selma Mahmutovic and Raymond, {Donald D.} and Taleen Dilanyan and Takaaki Koma and John Manning and Sundaresh Shankar and Levis, {Silvana C.} and Briggiler, {Ana M.} and Enria, {Delia A.} and Wucherpfennig, {Kai W.} and Slobodan Paessler and Jonathan Abraham",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-04271-z",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses

AU - Clark, Lars E.

AU - Mahmutovic, Selma

AU - Raymond, Donald D.

AU - Dilanyan, Taleen

AU - Koma, Takaaki

AU - Manning, John

AU - Shankar, Sundaresh

AU - Levis, Silvana C.

AU - Briggiler, Ana M.

AU - Enria, Delia A.

AU - Wucherpfennig, Kai W.

AU - Paessler, Slobodan

AU - Abraham, Jonathan

PY - 2018/12/1

Y1 - 2018/12/1

N2 - While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern.

AB - While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern.

UR - http://www.scopus.com/inward/record.url?scp=85047008908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047008908&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-04271-z

DO - 10.1038/s41467-018-04271-z

M3 - Article

C2 - 29760382

AN - SCOPUS:85047008908

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1884

ER -